How Pharma Connect Navigator Matches Biotech Programs With CDMOs

Many sourcing tools begin with a list of companies and ask users to filter it.

PCN starts with the manufacturing program.

A biotech, pharmaceutical, or CMC team defines what it is developing, where the program is in development, what manufacturing services it needs, which technical requirements matter, and which operational constraints may influence partner selection.

PCN then evaluates potential manufacturing partners against those requirements.

The methodology recognizes an important principle:

Not every sourcing criterion should behave the same way.

Some project requirements may be sufficiently important that failure to satisfy them makes a CDMO an inappropriate candidate for the program.

Other criteria are better treated as relative preferences that help distinguish between otherwise viable manufacturing partners.

PCN's algorithm therefore combines multiple forms of decision logic.

The result is more sophisticated than a static directory filter and more structured than asking a generic recommendation system to suggest manufacturers.

PCN's sourcing workflow can be summarized as:

1. DEFINE→
2. QUALIFY→
3. PRIORITIZE→
4. MATCH→
5. COMPARE→
6. DILIGENCE→
7. CONNECT

Each stage solves a different part of the CDMO selection process.

A useful CDMO recommendation requires significantly more context than knowing whether a program involves a small molecule, biologic, or advanced therapy.

PCN begins by structuring the manufacturing requirements of the program.

Depending on the project, relevant inputs can include:

• modality
• development stage
• regulatory and compliance requirements
• required manufacturing services
• technical capabilities
• support services
• batch or manufacturing scale
• anticipated project kickoff
• project budget
• geographic preferences
• target regulatory markets
• facility requirements
• equipment or process requirements where applicable
• partner type
• other operational considerations relevant to the sourcing decision

These inputs create the project profile against which potential CDMOs are evaluated.

The purpose is to move the sourcing question away from:

“Which CDMOs exist?”

and toward:

“Which CDMOs appear capable of supporting this particular manufacturing program?”

PCN does not treat every company in its database as equally relevant to every project.

The matching system evaluates structured sponsor requirements against structured CDMO and facility information.

The underlying algorithm uses different forms of matching logic depending on the nature of the requirement.

Some criteria can function as qualification gates.

Others contribute to the relative fit of otherwise viable manufacturing partners.

This distinction reflects how CDMO shortlisting is approached in real CMC sourcing work.

A sourcing team must differentiate between:

requirements that materially determine whether a supplier can support the program

and

preferences that help determine which capable supplier may be more attractive.

PCN's methodology is designed around that distinction.

We intentionally do not publicly disclose which individual fields use specific internal qualification treatments, thresholds, or scoring behavior.

Those mechanics are part of PCN's proprietary matching methodology.

What we do disclose is the underlying principle:

A CDMO should first appear capable of supporting the program before preference-based factors are allowed to make it look attractive.

There is no universally correct weighting for CDMO selection.

A preclinical biotechnology company preparing for first-in-human development may prioritize its manufacturing partner differently from a commercial-stage pharmaceutical company evaluating a second source.

One program may be highly sensitive to project timing.

Another may prioritize geography.

Another may require a particular manufacturing scale, specialized support service, operating model, or budget range.

PCN therefore allows users to customize selected sourcing priorities.

Priority factors can include areas such as:

• batch size
• development stage
• project kickoff
• budget
• geography
• support services

Adjustable multipliers allow the matching model to better reflect the user's actual sourcing priorities rather than forcing every manufacturing program into the same static ranking model.

The question becomes less:

“Which CDMO has the highest generic score?”

and more:

“Which CDMOs appear to align most closely with the requirements and priorities of this specific program?”

Once the program requirements and priorities are defined, PCN evaluates eligible manufacturing partners and generates project-specific matches.

Results can include a Match %.

That percentage should be interpreted carefully.

What the PCN Match % Means

A PCN Match % represents the degree of alignment between a specific manufacturing program and the structured information available for a potential CDMO or facility.

Match % is a project-fit signal. It is not a universal CDMO quality score.

It helps users compare how closely different potential manufacturing partners align with the requirements they have entered.

What the PCN Match % Does Not Mean

A Match % is not:

• a universal measure of CDMO quality
• an FDA or regulatory approval
• a prediction of project success
• a guarantee of manufacturing capacity
• a guarantee that a CDMO will accept the project
• a substitute for technical diligence
• a substitute for quality review
• a replacement for a site audit
• a formal vendor qualification
• an endorsement of one manufacturer for every type of program

A CDMO could be an excellent manufacturing organization and still receive a relatively weak match for a particular project.

Likewise, a strong project fit does not eliminate the need for sponsor diligence.

Project fit and manufacturer quality are related sourcing questions, but they are not the same question.

One of the limitations of company-level CDMO directories is that manufacturing capabilities can vary significantly across facilities operated by the same organization.

A global CDMO may operate multiple manufacturing sites with different:

• technologies
• equipment
• production scales
• dosage forms
• modalities
• regulatory histories
• development capabilities
• support services
• geographic advantages

For that reason, PCN incorporates facility-level information where available.

This allows users to investigate not only:

“Does this company offer the service?”

but also:

“Which facility appears relevant to this particular program?”

That distinction matters.

Manufacturing execution occurs at a specific facility, not at a corporate logo.

A company-level capability claim does not automatically mean every site operated by the organization can support the same work.

Facility-level information can therefore make a CDMO shortlist substantially more useful.

Matching is intended to narrow the universe of potential partners.

It is not the end of the sourcing process.

Once potential CDMOs have been identified, PCN helps users investigate the characteristics that distinguish them.

Depending on available information, CDMO and facility records can include areas such as:

• supported modalities
• target client types
• manufacturing services
• primary capabilities
• batch or manufacturing scale
• supported development stages
• regulatory or GMP information
• manufacturing equipment
• facilities
• geographic coverage
• typical project budget ranges
• project kickoff expectations
• support services
• other relevant manufacturing attributes

The objective is to give sponsors enough structured information to move from a broad universe of manufacturers toward a more defensible shortlist.

PCN's matching methodology was not adapted from a generic product-recommendation engine.

It was developed specifically for CDMO sourcing.

The framework is derived from the decision logic, established CMC practices, and industry-standard considerations used by experienced CMC professionals when evaluating and shortlisting manufacturing partners for biotechnology and pharmaceutical programs.

These principles were translated into structured criteria that a software system can evaluate consistently across potential partners.

The resulting approach combines:

CMC sourcing logic + structured manufacturing data + algorithmic evaluation + sponsor-defined priorities

That combination matters because CDMO selection is not a keyword-matching exercise.

A useful sourcing system must account for the fact that manufacturing-partner selection can involve:

• technical qualification
• development stage
• manufacturing modality
• process requirements
• operational requirements
• scale
• facility fit
• regulatory considerations
• timing
• geography
• commercial constraints
• sponsor preferences

PCN was built specifically for that decision environment.

PCN believes users should understand the principles behind a matching system without requiring the company to disclose the proprietary mechanics that make that system valuable.

We therefore publicly explain:

• the types of project information considered
• the distinction between qualification and preference
• the existence of weighted project-fit factors
• the role of customizable priority multipliers
• the concept of project-specific matching
• the role of facility-level information
• the role of preliminary regulatory context
• the meaning and limitations of Match %
• the broader sourcing workflow

At the same time, PCN protects the internal methodology used to calculate results.

This allows PCN to remain transparent about the logic and data categories behind matching without exposing the underlying intellectual property.

A sophisticated matching algorithm is only as useful as the information it evaluates.

For that reason, PCN treats data provenance, source quality, and record transparency as important parts of the sourcing process.

CDMO and facility information within PCN can originate from several different source types.

Understanding where a piece of information came from is important because not every data point carries the same evidentiary weight.

When PCN administratively creates a CDMO or facility record, information can be compiled from relevant public sources.

A primary source is the CDMO's own official website and published company materials.

Information can include publicly disclosed details about:

• manufacturing capabilities
• manufacturing facilities
• services
• modalities
• equipment
• regulatory support
• geographic presence
• development-stage support
• manufacturing scale
• other relevant technical or operational attributes

Using official company sources helps reduce dependence on third-party summaries that may be outdated, incomplete, or divorced from the manufacturer's current public information.

However, information published by a manufacturer should still be interpreted according to its source.

A company stating that it offers a capability is not the same thing as an independent sponsor formally qualifying that capability for a particular program.

PCN is designed to make the sourcing process more transparent, not to erase that distinction.

CDMOs can claim or manage their presence in PCN.

When an authorized CDMO representative enters, updates, or confirms information directly, the platform can incorporate data provided by the organization itself.

This can provide more current or detailed information than may be available on a public corporate website.

CDMO-entered information can include areas such as:

• manufacturing capabilities
• supported modalities
• facilities
• equipment
• manufacturing scale
• service offerings
• development-stage support
• other relevant profile information

Direct CDMO participation can improve the completeness and usefulness of a record.

At the same time, CDMO-entered information should be distinguished from information independently validated by a sponsor through formal diligence.

The provenance of the data matters.

PCN also incorporates regulatory information from authoritative public sources.

For U.S. regulatory information, PCN retrieves relevant information from FDA public databases and associates manufacturing facilities with FDA records using Facility Establishment Identifier, or FEI, numbers.

FEI numbers provide a more precise way to connect an establishment with relevant FDA records than relying only on a company name.

This is important because:

• corporate names can change
• subsidiaries can differ from parent companies
• facilities may operate under names different from the corporate brand
• ownership can change
• one CDMO can operate numerous facilities with different regulatory histories

Facility-level identifiers help PCN associate regulatory information with the manufacturing establishment to which it relates.

Where available and applicable, this regulatory context can include information such as:

• FDA inspection information
• Form FDA 483 observations
• FDA Warning Letters
• establishment-level regulatory records
• other relevant publicly available FDA information

The purpose is to bring regulatory context closer to the CDMO sourcing workflow rather than requiring users to independently search multiple disconnected sources for every potential manufacturing partner.

A Form FDA 483 should not automatically be interpreted as evidence that a CDMO is unsuitable.

FDA issues a Form 483 at the conclusion of an inspection when investigators have observed conditions they believe may constitute violations of applicable requirements.

A Form 483 is not by itself a final agency determination of regulatory noncompliance.

Context matters.

When reviewing regulatory history, sponsors may need to consider questions such as:

• What did the observations involve?
• When did the inspection occur?
• Were similar observations repeated?
• Which facility was inspected?
• Are the observations relevant to the proposed manufacturing program?
• What corrective actions were taken?
• Were subsequent inspections conducted?
• Were later regulatory actions issued?
• What does the broader inspection history of the facility show?

PCN therefore does not treat a Form 483 as a simplistic pass/fail indicator.

Its purpose is to surface relevant regulatory context and help sponsors identify questions that deserve further investigation.

FDA Warning Letters can provide another layer of regulatory context where relevant public records can be appropriately associated with a facility or organization.

Warning Letters should also be interpreted carefully.

The presence of a historical regulatory action does not automatically determine whether a facility is appropriate for a current manufacturing project.

Likewise, the absence of a publicly identified Warning Letter does not establish that a facility carries no regulatory risk.

Regulatory history is one component of diligence.

PCN's role is to help surface relevant information and connect it to the sourcing process.

The sponsor remains responsible for interpreting that information within the context of its own program and conducting appropriate formal diligence.

Not all manufacturing information should be treated as equivalent evidence.

PCN's data model can distinguish information originating from different source types.

1. 1

   Authoritative Regulatory Sources

   Information retrieved from government or regulatory databases, including relevant FDA records associated with manufacturing establishments through FEI numbers.

2. 2

   Official CDMO Sources

   Information compiled from the manufacturer's official website, facility pages, technical materials, company disclosures, or other official public sources.

3. 3

   CDMO-Entered Information

   Information entered, updated, or confirmed by an authorized representative of the CDMO.

4. 4

   PCN-Compiled Information

   Structured information compiled by PCN from relevant public sources and organized for sourcing and comparison.

5. 5

   Information Requiring Further Verification

   Information for which publicly available evidence may be incomplete, ambiguous, outdated, or insufficient for a definitive conclusion.

This distinction is important because:

Unknown information should not silently become assumed information.

When a sourcing decision involves regulatory exposure, development timelines, manufacturing risk, and significant capital, uncertainty itself can be important information.

Manufacturing information is not always complete.

CDMO websites vary significantly in the amount of technical information they make public.

One manufacturer may publish detailed equipment lists, production ranges, site-specific capabilities, and development services.

Another may provide only broad corporate descriptions.

PCN's internal methodology includes proprietary methods for handling incomplete information.

Those methods are not publicly disclosed.

The broader principle is straightforward:

Absence of information is not always evidence of absence.

Users should be able to distinguish between:

• a documented capability
• a manufacturer-reported capability
• a regulatory data point
• a CDMO-entered data point
• an unknown or missing field
• a requirement that still needs clarification

Missing data can itself become a diligence question.

It should not automatically be converted into an unsupported positive or negative conclusion.

PCN is designed to improve the early and middle stages of CDMO sourcing.

It can help users:

• define manufacturing requirements
• identify plausible manufacturing partners
• prioritize potential partners
• compare CDMOs
• investigate facility-level information
• review preliminary regulatory context
• identify open diligence questions
• request introductions

PCN does not replace the formal diligence required before selecting or contracting with a manufacturing partner.

Depending on the program, sponsors may still need to perform activities such as:

• technical assessments
• quality-system evaluation
• formal supplier qualification
• GMP audits
• regulatory review
• financial diligence
• legal review
• cybersecurity review
• site visits
• quality agreements
• contracting
• capacity confirmation
• project-specific feasibility assessment

PCN helps narrow and structure the sourcing process.

The final manufacturing-partner decision remains the responsibility of the sponsor.

A manufacturing facility may possess the appropriate technology, equipment, expertise, and scale while lacking availability during the sponsor's required project window.

For that reason, a PCN match should not automatically be interpreted as a guarantee of:

• current manufacturing capacity
• a specific production slot
• project acceptance
• timeline compatibility
• commercial terms
• technical feasibility

Manufacturing capability and manufacturing availability are different questions.

Capacity and availability intelligence are being developed as a separate part of PCN's product experience.

Until availability is specifically confirmed, it should remain an open sourcing question.

A useful shortlist only matters if sponsors can act on it.

PCN therefore connects matching with structured sponsor-to-CDMO introductions.

After reviewing potential manufacturing partners, sponsors can request an introduction.

The structured information already supplied about the manufacturing program can help provide the CDMO with relevant context about the opportunity.

An introduction can move through statuses such as:

Pending → Accepted → Declined

Sponsor identity can remain controlled until the appropriate point in the introduction workflow.

When the CDMO accepts the introduction, the parties can continue the conversation and determine whether deeper technical discussions make sense.

The objective is to improve the quality of the connection for both sides.

Sponsors can spend less time contacting manufacturers that appear poorly aligned with the project.

CDMOs can receive more structured opportunities with clearer manufacturing requirements.

A traditional directory generally helps answer:

“Which companies operate in this manufacturing category?”

PCN is designed to help answer:

“Which manufacturing partners appear to fit my specific program?”

A directory may provide:

• company names
• locations
• broad service categories
• company descriptions

PCN adds a project-specific decision layer that can include:

• structured program requirements
• qualification logic
• weighted project-fit evaluation
• customizable priority multipliers
• Match %
• facility-level context
• preliminary regulatory information
• structured comparison
• sponsor-to-CDMO introductions

Directories can still be useful sources of information.

PCN is not designed to eliminate every other research source.

It is designed to make the sourcing process more structured, explainable, and actionable.

There is no universally best CDMO.

The right manufacturing partner for one program may be inappropriate for another.

The partner suitable for a preclinical small-molecule program may be entirely different from the right partner for:

• an AAV gene therapy
• a monoclonal antibody
• an antibody-drug conjugate
• an mRNA product
• a sterile injectable
• an oral solid dosage form

Even within the same modality, differences in:

• development stage
• manufacturing scale
• technical requirements
• geography
• regulatory strategy
• project timing
• required services
• budget

can materially change the appropriate shortlist.

That is why PCN focuses on:

Project fit rather than universal ranking.

Transparency also means being clear about the limitations of structured matching.

PCN does not claim that an algorithm can know everything necessary to select a manufacturing partner.

Successful CDMO relationships can depend on variables that are difficult or impossible to represent fully in structured data, including:

• technical nuance
• communication quality
• responsiveness
• team chemistry
• negotiation
• changing capacity
• project-specific feasibility
• confidential technical information
• evolving regulatory conditions
• sponsor-specific risk tolerance

Matching should therefore be viewed as a way to improve the quality of the shortlist and the questions a sponsor asks.

It should not eliminate professional judgment.

Experienced CMC professionals bring judgment that cannot always be reduced to a database field or mathematical weight.

PCN is designed to make the more repeatable parts of the sourcing process more efficient.

By structuring manufacturing-partner research and comparison, PCN can reduce time spent on activities such as:

• repetitive internet research
• manual spreadsheet comparisons
• broad capability screening
• disconnected regulatory searches
• untargeted supplier outreach

That can allow CMC professionals to spend more time on areas where human expertise matters most:

• interpreting technical fit
• evaluating development risk
• preparing manufacturing strategy
• challenging supplier assumptions
• assessing tradeoffs
• conducting diligence
• managing technology transfer
• negotiating an appropriate path forward

PCN can also connect users with experienced CMC professionals when additional human guidance is useful.

1. Project Fit Is More Useful Than Universal Ranking

A CDMO should be evaluated against the needs of the specific manufacturing program.

2. Qualification Should Precede Preference

A manufacturer should not rank highly because of secondary preferences if it fails to satisfy a requirement important enough to determine basic suitability.

3. Different Criteria Should Not Be Treated Identically

Certain requirements may materially determine eligibility, while others are better used to compare otherwise viable options.

4. Sponsors Should Be Able to Adjust Priorities

Different programs face different constraints. The matching model should be able to reflect those differences.

5. Facilities Matter

Company-level capability claims do not necessarily describe what an individual manufacturing site can execute.

6. Data Provenance Matters

An FDA record, an official CDMO website statement, a CDMO-entered field, and an unknown data point should not all be treated as equivalent evidence.

7. Missing Information Should Remain Visible as Uncertainty

Unknown information should not silently become a factual conclusion.

8. Regulatory Information Requires Context

A regulatory observation should inform diligence rather than automatically determine partner suitability.

9. Matching Should Be Explainable

Users should understand the categories and principles influencing recommendations even when PCN's proprietary algorithm remains protected.

10. Software Supports Professional Judgment

A sourcing algorithm can improve a shortlist. It does not replace CMC expertise, sponsor diligence, quality review, or formal supplier qualification.

11. The Goal Is Not the Score

The ultimate purpose of matching is not to generate a percentage.

It is to help the right sponsor and the right manufacturing partner determine whether there is a credible basis for working together.

Finding a CDMO should not require starting with hundreds of company names and hoping the right manufacturer appears somewhere in the list.

PCN starts with the program.

Define what you are developing.

Specify what the manufacturing partner needs to support.

Identify which requirements are essential.

Customize what matters most.

Find CDMOs and facilities that appear to fit.

Compare the available evidence.

Investigate the open questions.

Then start a qualified conversation.